Supporting Lifelong Care for Hereditary Cancer Gene Carriers: The Importance of the UKCGG Consensus on Recontact and Follow-up
The publication of the UK Cancer Genetics Group (UKCGG) consensus statement on recontact and follow-up for individuals with hereditary breast and ovarian cancer susceptibility gene variants in the Journal of Medical Genetics represents a significant advance in the long-term management of individuals with inherited cancer predisposition. The multidisciplinary consensus provides, for the first time, nationally agreed recommendations on when and how healthcare professionals should recontact individuals carrying pathogenic variants in hereditary cancer susceptibility genes, helping to ensure that patients continue to benefit from advances in clinical knowledge throughout their lives.
Historically, follow-up arrangements for individuals with pathogenic variants in genes such as BRCA1, BRCA2, PALB2, ATM, CHEK2, RAD51C, RAD51D, BRIP1 and the Lynch syndrome genes have varied considerably between centres. While many patients receive comprehensive counselling at the time of diagnosis, clinical recommendations evolve over time as new evidence emerges regarding cancer risks, surveillance programmes, risk-reducing surgery, reproductive options and family management. Without structured mechanisms for recontact, there is a risk that patients may miss opportunities to benefit from these developments.
The consensus addresses this challenge by defining best-practice recommendations for age-specific recontact, referral to specialist services and the information that should be revisited throughout a patient’s lifetime. Rather than viewing genetic counselling as a single event, the recommendations recognise hereditary cancer management as a lifelong pathway that adapts to changing clinical evidence and changing patient needs.
The publication also acknowledges the practical challenges facing NHS services. Delivering proactive recontact requires appropriate infrastructure, workforce capacity and sustainable funding. The consensus therefore not only establishes best practice but also highlights the additional resources required to implement these recommendations effectively across the UK. This recognition is particularly important as genomic testing continues to expand and increasing numbers of individuals require long-term management.
Importantly, the guidance reinforces that responsibility for long-term care extends beyond the initial genetic test result. As evidence evolves, surveillance recommendations change and new preventive interventions become available, healthcare professionals need mechanisms to ensure that patients receive updated information that may influence their clinical management. Establishing nationally agreed principles for recontact provides an important framework for delivering truly lifelong genomic care.
For Ms Kiesel, the publication demonstrates the value of multidisciplinary collaboration in addressing one of the most important practical challenges facing cancer genetics services. By bringing together expertise from clinical genetics, oncology, surgery, genetic counselling and laboratory medicine, the UKCGG has produced guidance that supports more consistent, patient-centred follow-up while preparing services for the continued growth of genomic medicine.
Ultimately, the consensus is not simply about scheduling future appointments. It represents a commitment to ensuring that individuals living with hereditary cancer susceptibility continue to receive timely, evidence-based advice throughout their lives. By promoting equitable follow-up, improving communication and supporting consistent clinical practice, the recommendations provide an important foundation for the future delivery of hereditary cancer services across the UK.